BENZNIDAZOLE
PeakSMbenznidazole
NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
BENZNIDAZOLE (benznidazole) is [see microbiology ( )] . First approved in 2017.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Benznidazole is an oral tablet nitroimidazole antiparasitic agent approved in 2017 for treating Chagas disease caused by Trypanosoma cruzi infection. It works by disrupting the parasite's DNA and energy metabolism, effectively killing the organism in infected patients. This is a specialized infectious disease therapy with limited but critical market relevance in endemic regions.
Peak
Peak lifecycle status indicates stable commercial operations with established market presence, supporting mid-sized commercial and medical affairs teams.
Mechanism of Action
[see Microbiology ( )] .
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on benznidazole offers a specialized career path in rare/neglected tropical disease treatment, with exposure to niche market dynamics, global health stakeholder management, and differentiated commercial strategies. The product's peak lifecycle and limited competitive pressure create a stable environment for focused brand building and medical education in an underserved therapeutic area.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.